Merck Ventures

A corporate VC

General information

HQ

Amsterdam, Noord-Holland

Description

We drive innovation and back entrepreneurs through equity investments and hands on support in fields that could impact the vitality and sustainability of Merck’s current and future businesses. We are the strategic, corporate venture capital arm of Merck. Our mandate is to invest in innovative technologies and products with the potential to significantly impact Merck’s core business areas. From our headquarters in Amsterdam and offices in the US and Israel, we invest globally in transformational ideas driven by great entrepreneurs. We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success. We have a significant focus on early stage investing and company creation including the creation of spin-offs to leverage Merck’s science and technology base.

Team

Roel Bulthuis (Senior Vice President & Managing Director at Merck Ventures), Jasper Bos (Vice President), Edwin Kliphuis (Investment Director)

Contact information

Investment information

Investment type

Seed, Series A, Series B

Investment size

From a EUR 500k up to EUR 15m over the life cycle of a company

Investing in

Biotech, Medtech, HealthTech. Performance materials, clean tech, tech, agro-tech, food-tech.

Investments made

The portfolio is now 27 active companies. Details on the website

Exits

Epitherapeutics, ObsEva, Poxel, Galecto, Padlock, Ambrx, Birdrock Bio, Neviah Genomics, Progyny